Cellectar Biosciences Chief Scientific Officer Receives International Recognition for Pioneering Research Nov 20, 2015
Cellectar Biosciences Converts Patent Application for Phospholipid-Ether Analogs as Cancer Targeting Drug Vehicles Nov 10, 2015
Cellectar Biosciences to Host Conference Call on November 12th to Discuss Third Quarter Financial Results and Provide Clinical Development Program Update Nov 5, 2015
Cellectar Biosciences Provides Phospholipid Drug Conjugate (PDC) Platform Development Update Nov 2, 2015
Cellectar Biosciences Awarded $2.3M National Cancer Institute Fast-Track SBIR Grant to Advance Phospholipid Drug Conjugate (PDC) Delivery Platform Oct 1, 2015
